Wealth Advisory Solutions LLC Has $4.20 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Wealth Advisory Solutions LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 13.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,793 shares of the company's stock after selling 3,900 shares during the period. Zoetis makes up about 1.2% of Wealth Advisory Solutions LLC's portfolio, making the stock its 22nd largest holding. Wealth Advisory Solutions LLC's holdings in Zoetis were worth $4,202,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in ZTS. Mizuho Securities USA LLC lifted its holdings in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Zoetis by 296.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock worth $144,917,000 after acquiring an additional 665,331 shares during the period. Nordea Investment Management AB lifted its holdings in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock worth $336,266,000 after acquiring an additional 572,511 shares during the period. Holocene Advisors LP bought a new position in Zoetis in the 3rd quarter valued at approximately $110,809,000. Finally, Alecta Tjanstepension Omsesidigt bought a new position in Zoetis in the 4th quarter valued at approximately $83,835,000. Institutional investors own 92.80% of the company's stock.

Remove Ads

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Trading Up 1.8 %

Shares of ZTS stock traded up $3.09 during trading hours on Friday, hitting $170.34. 3,296,788 shares of the company's stock traded hands, compared to its average volume of 3,274,650. The stock's 50 day simple moving average is $166.72 and its 200 day simple moving average is $176.83. The stock has a market cap of $76.28 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is presently 36.56%.

Analysts Set New Price Targets

ZTS has been the subject of several research reports. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Morgan Stanley dropped their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 price objective for the company. Finally, StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has a consensus rating of "Buy" and a consensus target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.